Ostrava 9, Czech Republic
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
Phase
3Span
101 weeksSponsor
Alumis IncOstrava
Recruiting
Dose Escalation for SBRT of Recurrent VT Ventricular Tachyarrhythmia - a Single Center, Phase II Clinical Trial
Phase
1Span
340 weeksSponsor
University of ZurichOstrava
Recruiting
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy
Subjects will be randomized in a 2:1 ratio to receive either tinlarebant or placebo. The study treatment will be administered orally once daily from baseline (Day 1) through the final day of Month 24.
Phase
3Span
227 weeksSponsor
Belite Bio, IncOstrava
Recruiting
Ostrava
Recruiting
Healthy Volunteers
1-4 of 4